02 December 2024
02 December 2024
The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive treatment.
The ESMP platform enables marketing authorisation holders to report shortages and will be mandatory from 2025.
The government said that men are less likely than women to seek medical help, particularly for mental health issues.
GVHD causes the immune cells of a stem cell donor to attack the recipient's body by mistake.
The topical cream is currently being developed by researchers.
The deal encompasses UCB's Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Give your business an edge with our leading industry insights.
